GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Ms. Whitaker is an accomplished C-suite leader, most recently as Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's ...

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' ...

GSK PLC closed 21.39% short of its 52-week high of £18.24, which the company reached on May 16th.

UTI sufferers have a new treatment option—and it's the first new class of antibiotics the FDA has approved for urinary tract ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

GSK PLC closed 18.56% short of its 52-week high of £18.24, which the company achieved on May 16th.